Notably, the HDAC inhibitor, sodium phenylbutyrate-taurursodiol, was evaluated in Phase II clinical trials for amyotrophic lateral sclerosis and provided 6.5 months more survival than a placebo (Paganoni et al., 2021). This evidence concerns the gene HDAC9 and amyotrophic lateral sclerosis.